Imagion Biosystems Limited announced it has entered into a Joint Development Agreement with Global Cancer Technology (GCT), to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. Under the terms of the Agreement, Imagion will be paid for certain R&D services while gaining an ownership interest in the arising GCT nanoscintillator product.